Kornimate/medical-research-clean huggingface dataset:
rna precision oncology in advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel oncotreat platform. the primary objective of this study is to assess the feasibility of implementing the oncotreat framework in patients with newly diagnosed, untreated metastatic pancreatic adenocarcinoma.

pancreatic ductal adenocarcinoma (pda) is a major health problem in the united states and throughout the world. pancreatic ductal adenocarcinoma (pda) has the worst prognosis of any major malignancy in the united states and, unlike other common cancers, annual deaths from pda are rising. during 2017, it is estimated that 53,670 people were diagnosed with pda and approximately 43,090 people died from pda in the u.s. despite recent advances, cytotoxic chemotherapy for pda has been disappointing with response rates of 20-30% for the most active regimens and little activity for targeted therapies. even among the small subset of patients who are suitable for surgical resection at the time of diagnosis, complete resection is followed by recurrence in \>90% of patients without further systemic therapy, with a median time to recurrence of 6.9 months. thus all pda patients require systemic chemotherapy and more effective regimens are urgently needed. previous versions of this record contained reference to an observational arm in error. the observational arm has been removed from the record for consistency with the study protocol.

Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent for the trial. * age ≥18 years of age on day of signing informed consent. * have histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma or be willing to undergo a biopsy with confirmed pathology prior to starting therapy. * have untreated disease that is unresectable due to being metastatic or locally advanced without potential of surgery as assessed by the treating physician. * subjects who have documented disease recurrence greater than 6 months after completing neoadjuvant or adjuvant chemotherapy for limited disease will be eligible for the study. * have a predicted life expectancy of greater than 6 months. * subjects must have a plan to obtain a new core biopsy of a primary and/or metastatic lesion planned as part of routine care for which consent is obtained separately or (b) consent to be biopsied to satisfy the tissue requirements of this protocol. exclusion criteria: has previously received neoadjvuant or adjuvant chemotherapy for pancreatic cancer unless greater than 6 months has passed since completion of adjuvant or neoadjuvant chemotherapy and initiation of therapy for recurrent or metastatic disease.

Keywords: pancreatic ductal adenocarcinoma (pda) precision medicine
comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: scale - maintenance

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in north america. the aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood). trial has following trial periods: a 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).


Eligibility criteria:
inclusion criteria: * body mass index (bmi) of either 30 kg/m\^2 or more or bmi of less than 30 kg/m\^2 to 27 kg/m\^2 with presence of co-morbidities * stable body weight during the previous 3 months (less than 5 kg self-reported weight change) * previously undergone dietary weight loss and was not able to maintain reduced weight exclusion criteria: * diagnosis of type 1 or type 2 diabetes * previous treatment with glp-1 (glucagon-like peptide-1) receptor agonists (including liraglutide or exenatide), within the last 3 months * visit 1 thryoid stimulating hormone (tsh) outside of the range of 0.4-6.0 miu/l * history of chronic pancreatitis or idiopathic acute pancreatitis * obesity induced by other endocrinologic disorders (e.g., cushing syndrome) * current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial * current participation in an organized diet reduction program (or within the last 3 months) * currently using or have used within three months before this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin * previous surgical treatment for obesity (excluding liposuction if performed more than one year before trial entry) * history of major depressive disorder or a phq-9 (patient health questionnaire-9) score of more than 15 within the last 2 years or history of other severe psychiatric disorders or diagnosis of an eating disorder * subjects with a lifetime history of a suicide attempt or history of any suicidal behavior within the past month before entry into the trial
impact of prehabilitation in oncology via exercise- esophageal (improve-esophageal)

Conditions: Esophageal Cancer; Esophageal Carcinoma

Summary: the goal of this study is to (1) determine the feasibility of a prehabilitation exercise program (exercise before a medical treatment) in adults with esophageal cancer before surgery (esophagectomy). the pre-surgery exercise program will include resistance and aerobic training during the weeks before surgery. we will also assess pre-surgical care needs in adults with esophageal cancer. researchers will compare the exercise intervention to usual care- which is standard medical care and post-surgery surveillance/follow-up to understand the impact of exercise before surgery. we will follow-up with participants before surgery, and after surgery at 2 weeks, 6 weeks, and 4-months at appointments that coincide with clinical follow-ups. the main questions of this trials are: * is exercise before surgery for esophageal cancer feasible and acceptable to patients? * how does exercise before surgery change physical function and psychosocial health? * what are important pre-surgical needs for adults with esophageal cancer?


Eligibility criteria:
inclusion criteria: * men and women, age ≥ 18 years old * diagnosed with esophageal cancer * identified as esophagectomy surgery candidates at hillman cancer center or upmc shadyside * ≥ 2 weeks until scheduled esophagectomy * currently completing, or completed neoadjuvant chemotherapy * ecog performance status scale score of ≤ 2 * ability to provide written informed consent * ability to understand, speak, and read english. exclusion criteria: * evidence in the medical record of an absolute contraindication for exercise (e.g., heart insufficiency \> nyha iii or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability) * any other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist * receiving non-esophagectomy related chemotherapy and/or radiotherapy * active infections, hemorrhages, and cytopenias that could place surgical patients at risk for further adverse events, deemed by the exercise interventionist, physician, and/or nurse

Keywords: prehabilitation exercise esophageal cancer neoadjuvant chemotherapy pre-surgical exercise
brain connectivity in age-related macular degeneration

Conditions: Age-Related Macular Degeneration

Summary: this study is to determine how cognitive deficits (e.g.,verbal fluency deficit) in patients with age-related macular degeneration (amd) relate to specific aspects of brain and function. the study team will assess whether the "brain signatures" associated with specific cognitive deficits differ in older adults with and without amd.


Eligibility criteria:
inclusion criteria: amd - vision loss attributable to amd controls * age match (± 5 yrs) * gender match * education match (± 4yrs) * normal macular exam exclusion criteria: amd * other significant eye pathology * mod/severe dementia * communication barrier that precludes testing controls * other significant eye pathology * mod/severe dementia * communication barrier that precludes testing mri subset * devices or material incompatible with 3.0 tesla mri * conditions that may interfere with interpretation of fmri (e.g. history of stroke, brain tumor or previous brain surgery; psychoactive medications; seizure disorder) * claustrophobia * left-handed * body weight \> 300 lbs * pregnant women
dynamic magnetic resonance imaging before and after vaginal prolapse repair

Conditions: Pelvic Organ Prolapse

Summary: this study is to describe the impact of vaginal reconstruction, including an intraperitoneal vaginal vault suspension for pelvic organ prolapse (pop) on pelvic anatomy using dynamic magnetic resonance imaging (mri) of the pelvis.

approximately 1 in 11 women will undergo surgery for pop by age 80 years. pop occurs due to a defect or weakness of the pelvic floor, resulting in the herniation of pelvic organs through the vagina. the goal of surgical interventions has historically been thought to restore normal pelvic anatomy. restoration of pelvic anatomy has been demonstrated following pelvic reconstructive surgery by way of significantly improved postoperative pelvic organ prolapse quantification (popq) scale measurements. furthermore, improved popq measurements have also been shown to be positively correlated with improved patient satisfaction. more recently, attention has turned toward using imaging studies to describe the postoperative anatomical changes seen in pelvic reconstructive surgery. the purpose of this study is to describe the impact of vaginal reconstruction, including an intraperitoneal vaginal vault suspension for pop on pelvic anatomy using dynamic mri of the pelvis. the primary aim is to compare postoperative dynamic pelvic mri measurements to preoperative measurements in patients who undergo prolapse repair vaginally including anterior, posterior and intraperitoneal vaginal vault suspension repairs for pop.

Eligibility criteria:
inclusion criteria: * adults 18 years of age or older * english-speaking * undergoing anterior, posterior and intraperitoneal vaginal vault suspension by a physician at cincinnati urogynecology associates, trihealth for the treatment of symptomatic pop * concomitant procedures such as hysterectomy, suburethral sling, bilateral salpingectomy or salpingooophorectomy * willingness to participate in study exclusion criteria: * unwillingness to participate in the study * pregnancy * contraindication to pelvic mri, such as a metal implanted device (excluding titanium) or claustrophobia * previous surgery for apical prolapse such as sacrocolpopexy or vaginal vault suspension, or transvaginal mesh for prolapse * physical or mental impairment that would affect the subject's ability to complete the dynamic mri, including patient's with dementia or those who have impaired mobility * known findings that may distort pelvic anatomy, such as a pelvic mass, congenital anomaly, or history of pelvic radiation
safety and efficacy study of botulinum toxin type a for the treatment of crow's feet lines and frown lines

Conditions: Facial Rhytides; Crow's Feet Lines; Glabellar Lines

Summary: this study will evaluate the safety and efficacy of botulinum toxin type a compared to placebo for the treatment of crow's feet lines and frown lines (facial rhytides) for patients who successfully completed study 191622-099.


Eligibility criteria:
inclusion criteria: * successfully completed study 191622-099 exclusion criteria: * known immunization or hypersensitivity to botulinum toxin of any serotype * anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment) * diagnosis of myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis * anticipated need for surgery or hospitalization during the study
reducing hiv risk among adolescents: evaluating heart for teens

Conditions: HIV Infections; Sexually Transmitted Diseases

Summary: this study evaluates an educational web-based intervention designed to increase adolescent boys' and girls' motivation and skills to engage in safer sexual behavior (heart: health education and relationship training). half of participants will receive heart and half of participants will receive growing minds, an attention-matched control website focused on growth mindsets of intelligence and self-regulation. the ultimate goal of this work is to help youth reduce their risk of hiv and other sexually transmitted diseases and to avoid unplanned pregnancies.

this study evaluates an educational web-based intervention designed to increase adolescent boys' and girls' motivation and skills to engage in safer sexual behavior (heart: health education and relationship training). half of participants will receive heart and half of participants will receive growing minds, an attention-matched control website focused on growth mindsets of intelligence and self-regulation. the ultimate goal of this work is to help youth reduce their risk of hiv and other sexually transmitted diseases and to avoid unplanned pregnancies. primary outcomes for this study include 1) acceptability of the program, 2) safer sex self-efficacy, and 3) safer sex intentions.

Eligibility criteria:
inclusion criteria: * 10th or 11th grader * able to read english exclusion criteria: * none
ocular changes with alpha-2 receptor agonist.

Conditions: Glaucoma, Suspect; Aberration, Corneal Wavefront

Summary: selective alpha-2 receptor agonists cause changes in intraocular pressure and pupillary size thus may affect patient quality of life.

in this research, we will analyze the effect of selective alpha-2 receptor agonists on the human eye and investigate ocular changes over 6 months after its topical use.

Eligibility criteria:
inclusion criteria: * glaucoma suspect cases. * post-refractive surgery cases. exclusion criteria: * cases with prostatic hyperplasia or diabetics that may alter the measurements of pupillary diameter. * cases with previous history of any retinal intervention or other drugs that may alter intraocular pressure measurements.

Keywords: glaucoma suspect post-lasik
efficacy and safety of oral valproic acid for retinitis pigmentosa

Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration

Summary: the purpose of this study is to evaluate the efficacy and safety of oral valproic acid to slow the progression of visual function and/or to improve the visual function in patients with retinitis pigmentosa (rp). enrolled subjects in valproic acid group will be treated with oral valproic acid 500mg daily for 48 weeks. visual function and safety will be assess before and after treatment (48 weeks) between valproic acid and control groups.

this study is designed as a single-site, interventional, prospective, non-randomized, controlled study of 200 participants. patients that participate in the study will be assigned to either valproic acid group or control in a 3:1 ratio.

Eligibility criteria:
inclusion criteria: * diagnosis of retinitis pigmentosa (rp) established by night blindness, visual field constriction, marked reduction of electroretinogram, and the clinical signs of rp in fundus examination * best corrected visual acuity of 20/200 or more on a snellen chart in at least one eye * intact visual field of 5 or more as measured by the kinetic perimetry * understand and sign the irb-approved informed consent document for the study * body weight: male (40 kg to 100 kg), female (40 kg to 80 kg) * must be able to swallow tablets * female subjects of childbearing potential must commit to practice acceptable methods of contraception exclusion criteria: * pregnant women * lactating mothers * medical problems that make consistent follow-up over the treatment period unlikely (e.g., stroke, myocardiac infarction, malignancy) or severe systemic disease * other ocular disease: retinal disease other than rp or cystoid macular edema, glaucoma, cataract worse than +2psc or infectious corneal disease * coagulation disorder or bleeding-tendency * liver dysfunction * renal dysfunction * history of pancreatitis * history of neurological disorders including epilepsy, history of brain injury or any organic brain disorders * history of mental disorders including schizophrenia, bipolar disorder, or suicidality * currently receiving valproic acid or other anti-convulsants * has taken one of the following drugs at least 4 weeks prior to enrollment as these drugs are specifically known to affect the progression of rp: vitamin a, lutein, omega-3 fatty acid, or any antioxidant which affect the blood flow of retina or retinal function.

Keywords: retinitis pigmentosa valproic acid
multimodal connectome study of brain tumor-operated patients

Conditions: Tumor, Brain

Summary: in this pilot study, the investigators propose a multimodal evaluation of the brain connectivity of brain tumor patients, in order to better understand the effects induced by focal lesions on brain structure and function, as well as brain plasticity mechanisms that may occur in such condition. the investigators aim at drawing a multimodal brain connectivity map of focally brain-damaged patients, with a view to improve onco-functional neurosurgical practices.

patients included in the present study will first perform the pre-operative mri (dmri and fmri) with a specific high resolution angular diffusion (hardi) sequence and a functional acquisition at rest. then, the investigators will record their cortico-cortical evoked potentials elicited by direct electrostimulation during the surgery, just before the tumor removal, following our usual protocol. finally, all data (clinical, diffusion, electrical and functional connectivity) will be processed and correlated to each other.

Eligibility criteria:
inclusion criteria: * all patients with brain tumor for removal * age \> 18 years * informed patient consent * membership of social security scheme exclusion criteria: * contraindication to mri * any subject with vascular stent implanted less than 6 weeks prior to the exam; * any subject carrying an intraocular or intracranial ferromagnetic foreign object close to nerve structures; * any subject carrying biomedical equipment such as a cardiac, neuronal or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained in the performance of mri in these subjects; * presence of more than one brain tumor * refusal of patient participation * pregnant or nursing women. a urinary pregnancy test will be conducted for women of childbearing age. the results will be communicated to the patient by a doctor of her choice. * person staying in a health or social establishment * person in emergency situation * vulnerable patient: deprived of liberty, guardianship, curators, or safeguarding of justice
comparison between 3-l and 4-l polyethylene glycol in bowel preparation

Conditions: Bowel Preparation Scale; Adenoma Detection Rate

Summary: high quality bowel preparation is essential for successful colonoscopy. this study aimed to assess the impact of the dose of polyethylene glycol(peg) on the quality of bowel preparation. this prospective, endoscopist-blinded, randomized, controlled study was conducted. 3l-group received 3 bags of peg and were instructed to drink 1l at 19:00 in the evening before the day of colonoscopy at a rate of 250 ml every 15 minutes, and to drink the remaining 2l 4 to 6 h before colonoscopy at the same rate. 4l-group received 4bags of peg and were instructed to drink 2 l at 19:00 in the evening before the day of colonoscopy at a rate of 250 ml every 15 minutes, and to drink the remaining 2l 4 to 6 h before colonoscopy at the same rate. the primary outcome was the quality of the bowel preparation according to the boston bowel preparation scale (bbps). the secondary outcomes included polyp detection rate (pdr), adenoma detection rate (adr), tolerance, and subjective feelings of patients.


Eligibility criteria:
inclusion criteria: 1. outpatients aged 18-75 years 2. referred for routine diagnostic colonoscopy 3. patients who have signed inform consent form exclusion criteria: 1. pregnancy or breastfeeding 2. allergy to purgatives 3. suspected intestinal obstruction, stricture, or perforation 4. hemodynamic instability 5. impaired swallowing reflex or mental status 6. severely medical status, such as new york heart association grade iii or grade iv congestive heart failure and severe renal failure 7. history of oesophagus、stomach 、duodenum、small intestine or colorectal surgery 8. participation declined.

Keywords: polyp detection rate adenoma detection rate boston bowel preparation scale
the v-wave shunt: fim safety and feasibility study

Conditions: Congestive Heart Failure

Summary: the v-wave atrial-septal shunt implant is intended for the reduction of elevated left atrial filling pressures ('left atrial decompression') in chronic, new york heart association (nyha) class iii -iv, heart failure (hf) patients. this is a first in man (fim) study, aimed to enable a first evaluation of the safety and performance of the v-wave shunt implant when implanted in chronic heart failure patients. prospective, open label, single-arm study with intra-patient comparisons (i.e. subjects' status will be compared to their pre-implant (baseline) status.

v-wave ltd, an israeli based medical device company, has developed the v-wave atrial-septal shunt, a permanent implant indicated for heart failure (hf) patients with elevated left atrial filling pressures (lap). the v-wave shunt, developed by v-wave ltd, has been designed specifically to meet the needs of an interatrial shunt and thus represents a dedicated device, to be implanted percutaneously in the interatrial septum creating an interatrial communication. this study aims to enable a first evaluation of the safety and performance of the v-wave shunt implant when implanted in heart failure patients with elevated lap. study endpoints were then chosen to portray both safety (device related major adverse cardiac and neurological events) as well as preliminary performance as assessed by a well characterized measure (e.g., lap which is known to be associated with the general state of the disease and most importantly left ventricular ejection fraction and cardiac function in general).

Eligibility criteria:
inclusion criteria: * patient is ≥ 18 and \< 85 years old * patient has chronic ischemic or non-ischemic cardiomyopathy nyha class iii or ambulatory class iv heart failure despite optimal medical therapy * patient lvef \> 15% and ≤ 40% * patient has elevated left atrial pressure (lap) * patient has normal right atrial pressure (rap) * bnp or ntprobnp levels are \>300 or \>1500 pg/ml, respectively exclusion criteria: * right heart failure * ongoing malignant disease * thromboembolic event within the last 6 months * acute or chronic renal insufficiency * congenital heart disease * severe pulmonary hypertension * atrial fibrillation (persistent/permanent) * severe mitral regurgitation * la thrombus or deep vein thrombosis (dvt) * severe restrictive or obstructive lung disease

Keywords: heart failure (hf) left atrial pressure